The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
 
Evan Justin Walker
Research Funding - CrystalGenomics, Inc. (Inst)
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Boehler Life Science Advice; BPGbio; ClearNote Health; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient; TD2; Vivacitus
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
Anthony F. Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
James Thomas D'Olimpio
Research Funding - CG Pharmaceuticals
 
J. Randolph Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals
Consulting or Advisory Role - Astellas Pharma; Corcept Therapeutics; Exelixis; Gilead Sciences; Istari; Notch Therapeutics; Regenacy Pharmaceuticals; Tempus
Research Funding - A2 Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Bold Therapeutics (Inst); Camurus (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Tesaro/GSK (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Amgen
 
Shou-Ching Tang
No Relationships to Disclose
 
Glenn Michelson
Other Relationship - Fore Biotherapeutics
 
Lorna Liganor
Employment - CG Pharmaceuticals
 
Sangsook Ahn Cho
Employment - CG Pharmaceuticals
 
Andrew H. Ko
Honoraria - Clinical Care Options; Gerson Lehrman Group; Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; FibroGen; Genentech; GRAIL; Ipsen; Merus; Roche/Genentech
Speakers' Bureau - Clinical Care Options
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst)